Portal de Periódicos da CAPES

Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery

2016; Elsevier BV; Volume: 12; Issue: 10 Linguagem: Inglês

10.1016/j.soard.2016.02.013

1878-7533

Juan José Gorgojo Martínez, Gara Feo-Ortega, Clara Serrano‐Moreno,

Metabolism, Diabetes, and Cancer

Current guidelines do not offer detailed recommendations on antidiabetic drug therapy in type 2 diabetes (T2D) after bariatric surgery (BS), and reported experience is scarce.To evaluate the effectiveness and tolerability of liraglutide at 2 years in patients with morbid obesity after undergoing BS and subsequent relapse, persistence, or new diagnosis of T2D, comparing the results with a cohort of nonsurgical diabetic patients also treated with liraglutide.Obesity clinic at a University Hospital.We conducted a retrospective study of 2 cohorts of patients (with and without previous BS) with T2D and obesity who had started treatment with liraglutide at least 2 years before their inclusion in the study. The main outcome measures were the differences in glycated hemoglobin (A1C) and weight at 104 weeks between both groups.A total of 164 patients were included, 15 with previous BS and 149 without BS. Mean baseline parameters were A1C 6.6% and body mass index 40.3 kg/m2 for the BS group, and A1C 7.5% and body mass index 39.7 kg/m2 for the non-BS group. At 2 years, A1C and weight were significantly decreased in both groups (BS group: ΔA1C -0.39%, Δweight -3.4 kg; non-BS group: ΔA1C -0.67%, Δweight -3.8 kg; all results P<.05), with no significant differences in A1C and weight reduction between both groups. There was a significant lower frequency of withdrawals due to all causes and a nonsignificant lower rate of vomiting and hypoglycemia in patients with BS.Liraglutide achieved a significant reduction in weight and A1C at 2 years in patients with T2D previously treated with BS, showing good gastrointestinal tolerance.